Literature DB >> 15006826

Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.

Beatriz Rosón1, Jordi Carratalà, Núria Fernández-Sabé, Fe Tubau, Frederic Manresa, Francesc Gudiol.   

Abstract

BACKGROUND: Early failure is a matter of great concern in the treatment of community-acquired pneumonia. However, information on its causes and risk factors is lacking.
METHODS: Observational analysis of a prospective series of 1383 nonimmunosuppressed hospitalized adults with community-acquired pneumonia. Early failure was defined as lack of response or worsening of clinical or radiologic status at 48 to 72 hours requiring changes in antibiotic therapy or invasive procedures. Concordance of antimicrobial therapy was examined for cases with an etiologic diagnosis.
RESULTS: At 48 to 72 hours, 238 patients (18%) remained febrile, but most of them responded without further changes in antibiotic therapy. Eighty-one patients (6%) had early failure. The main causes of early failure were progressive pneumonia (n = 54), pleural empyema (n = 18), lack of response (n = 13), and uncontrolled sepsis (n = 9). Independent factors associated with early failure were older age (>65 years) (odds ratio [OR], 0.35), multilobar pneumonia (OR, 1.81), Pneumonia Severity Index score greater than 90 (OR, 2.75), Legionella pneumonia (OR, 2.71), gram-negative pneumonia (OR, 4.34), and discordant antimicrobial therapy (OR, 2.51). Compared with treatment responders, early failures had significantly higher rates of complications (58% vs 24%) and overall mortality (27% vs 4%) (P<.001 for both).
CONCLUSIONS: Early failure is infrequent but is associated with high morbidity and mortality rates. Its detection and management require careful clinical assessment. Most cases occur because of inadequate host-pathogen responses. Discordant therapy is a less frequent cause of failure, which may be preventable by rational application of the current antibiotic guidelines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006826     DOI: 10.1001/archinte.164.5.502

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  43 in total

1.  What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.

Authors:  Simone Gattarello
Journal:  Curr Infect Dis Rep       Date:  2015-10       Impact factor: 3.725

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 3.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

4.  Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia.

Authors:  Samuel M Brown; Jason P Jones; Dominik Aronsky; Barbara E Jones; Michael J Lanspa; Nathan C Dean
Journal:  Respirology       Date:  2012-11       Impact factor: 6.424

Review 5.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

6.  Early cardiac arrest in patients hospitalized with pneumonia: a report from the American Heart Association's Get With The Guidelines-Resuscitation Program.

Authors:  Gordon E Carr; Trevor C Yuen; John F McConville; John P Kress; Terry L VandenHoek; Jesse B Hall; Dana P Edelson
Journal:  Chest       Date:  2011-12-22       Impact factor: 9.410

Review 7.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

8.  Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia.

Authors:  Kristoffer Strålin; Margit Staum Kaltoft; Helle Bossen Konradsen; Per Olcén; Hans Holmberg
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission.

Authors:  Oriol Sibila; G Umberto Meduri; Eric M Mortensen; Antonio Anzueto; Elena Laserna; Juan F Fernandez; Ali El-Sohl; Marcos I Restrepo
Journal:  J Crit Care       Date:  2012-12-21       Impact factor: 3.425

10.  The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.

Authors:  Alexandra McFarlane; Wendy Sligl
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.